ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Medroxyprogesterone Acetate

Also written as “Sayana Press”, “medroxyprogesterone acetate” and “TV-46046”.

Its studies are mostly in Neoplasms · Adenocarcinoma, led by 4 companies.

Drug pageMedroxyprogesterone Acetate: every studyAll 74 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jan 24, 201711 company-led studies, 1 open or runningNext primary completion: Nov 4, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizerits history only50 open or runningphase 4since Jan 24, 2017May 10, 2007none ahead
Teva Pharmaceutical Industriesits history only40 open or runningphase 1since Jan 26, 2009Jan 26, 2009none ahead
Merck11 open or runningphase 2since May 13, 2025May 13, 2025Nov 4, 2027phase 2 · NCT06979596
Takedaits history only10 open or runningphase 3since Nov 3, 2009Nov 3, 2009none ahead

Also a collaborator on its studies: MDS Pharma Services.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 13, 2025First study: phase 2 study in NeoplasmsFirst studyNCT06979596 · 250 planned · United States, Argentina, Brazil and more

Ahead

  1. Nov 4, 2027Primary completion: phase 2 study in NeoplasmsNCT06979596

TargetBeta

PGR →read by rule
“Progesterone receptor agonist”ChEMBL 37, by rule

Other programs on PGR

ProgramCompanyFurthest phaseStudies
LevonorgestrelruleBayerphase 456
drospirenoneruleestetraphase 420
Megestrol AcetateruleChangchun GeneScience Pharmaceuticalphase 419
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Utrogestanrulecalla-lily-clinical-care-ltdphase 11

Studies

The one study Merck leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06979596Neoplasms · United States, Argentina, Brazil and more2RecruitingNov 4, 2027250

How it is read

Names in the registry

  • “Sayana Press”, 2 entries
  • “medroxyprogesterone acetate”, 2 entries
  • “TV-46046”, 2 entries
  • “Premarin/MPA”, 2 entries
  • “Megestrol acetate/Medroxyprogesterone acetate”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.